Pharma Co. Must Face Investor Suit Over Cancer Drug Study
Spectrum Pharmaceuticals must face a consolidated proposed securities class action alleging it misled investors about a lung cancer treatment drug study after a New York federal judge decided Tuesday that the...To view the full article, register now.
Already a subscriber? Click here to view full article